New Prostate Cancer Test Significantly Improves Specificity of Screening

New Prostate Cancer Test Significantly Improves Specificity of Screening
Researchers have developed and validated a new diagnostic test to identify high-risk prostate cancer that reduces the number of unnecessary biopsies without sacrificing the sensitivity to correctly diagnose aggressive cancer. The research paper, entitled “Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study,” was published in The Lancet Oncology. The STHLM3 diagnostic study,

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *